Insight into chromatin therapies for breast cancer could aid personalized medicine
(Boston University School of Medicine) Most traditional chemotherapy for cancer has dangerous side effects, but new research is finding ways to develop 'targeted agents' that reduce the side effects and are better tailored to individual patient needs. While these innovations are exciting, a new study shows how certain cancer inhibitors need to be examined more carefully to better understand fine-grained effects and counter-effects, which could yield more effective and safer therapies.
ConclusionsOnco-Move is not likely to be cost-effective. Depending on the decision-makers ’ willingness-to-pay, OnTrack could be considered cost-effective in comparison with UC.Trial registration Clinical trial registration number of the Netherlands Trial Register —NTR2159.
Authors: Essel KG, Moore KN Abstract INTRODUCTION: Niraparib, an orally available selective inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP) is the first PARP inhibitor approved for use in patients with ovarian cancer who do not harbor a germline or somatic mutation in the breast cancer gene (BRCA). Overall niraparib is well tolerated and its toxicities, primarily hematologic, are manageable especially with recently released initial dose modification guidelines based on weight and baseline platelet count. The role of niraparib as maintenance following front-line platinum-based chemotherapy as well ...
Condition: Triple Negative Breast Cancer Interventions: Biological: adagloxad simolenin combined with OBI-821; Biological: Phosphate-buffered saline (PBS) Sponsor: OBI Pharma, Inc Not yet recruiting
CONCLUSIONS: It was found that most patients diagnosed with breast cancer showed dermatologic manifestations during the proposed cancer treatment. Patients undergoing radiotherapy and surgery showed skin changes with greater statistical significance.
We report the case of a 65-year-old woman with cutaneous metastasis from breast cancer treated 14 years back, manifested by extensive firm and infiltrated red-purple plaques on the sides of the trunk, with a course of six months. After evaluation, she was referred to the regional cancer center. She passed away one month and a half later.
ConclusionsThis work shows that PK-toxicity modeling provides insight into how the severity of key adverse events evolves over time and highlights the potential use to support decision making in drug development.
Authors: O'Conor CJ, Chen T, González I, Cao D, Peng Y Abstract Triple-negative breast cancer (TNBC) is an aggressive disease with poor outcome, and lacks targeted therapy. Recent studies suggest that cancer stem cells play an important role in tumorigenesis and tumor biology of TNBC. Both CD44+/CD24- and ALDH1+ breast cancer stem cells are enriched in TNBC and may contribute to the propensity of TNBC for chemotherapy resistance and tumor metastasis. There is new evidence to support the evaluation of cancer stem cells in TNBC for diagnostic purposes. Targeting cancer stem cells may also be a promising, novel...
CONCLUSION: Cellular expression of COL1A1 could promote breast cancer metastasis. COL1A1 is a new prognostic biomarker and a potential therapeutic target for breast cancer, especially in ER+ patients. PMID: 29906404 [PubMed - in process]
Conclusion From our experience, this treatment sequence allows patients to have an immediate gold standard reconstruction without an increase in surgical morbidity. It affords the benefits of IBR without concern in delaying adjuvant therapy and appears to be safe from an oncological perspective. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents | Abstract | Full text
A 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes.